Atrial natriuretic peptide (ANP) is a recently discovered hormone with diverse physiologic properties. Studies are elucidating the role of ANP in multiple pathologic conditions, but its exact importance remains unclear. The gene for mouse ANP has been cloned and sequenced in the sponsor's laboratory. The goal of the Phase I project will be to inactivate the ANP gene in mice. Specifically, the aims are to 1) Construct embryonic stem (ES) cells with a defective ANP gene by homologous recombination; 2) Microinject ES cells with the mutant ANP gene into mouse blastocysts; 3) Transfer these blastocysts into the uteri of pseudopregnant mice; 4) Determine which of the resulting chimeric mice have the mutant ANP gene in the germ line; 5) Interbreed these chimeras to produce mice homo- and heterozygous for the ANP gene deletion. Physiologic consequences of ANP deletion will then be assessed. It is expected that the heterozygotes will be viable; the viability of the homozygotes is less certain. If not viable, the developing ANP-/ANP- embryos will be studied histologically to define the effects of ANP deletion. During Phase II of this grant, similar methods will be used to further characterize the physiology of ANP by utilizing homologous recombination to inactivate the ANP receptor genes. These studies will aid in the investigation of ANP function in normal and pathologic states. This may prove to be of particular import in helping to understand the dysregulation of blood pressure and volume homeostasis seen in liver failure, heart disease, renal disease, and hypertension.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Physician Scientist Award (K11)
Project #
5K11DK002138-04
Application #
2133891
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1992-09-01
Project End
1997-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Pollak, M R; Delaney, V B; Graham, R M et al. (1996) Gitelman's syndrome (Bartter's variant) maps to the thiazide-sensitive cotransporter gene locus on chromosome 16q13 in a large kindred. J Am Soc Nephrol 7:2244-8
Hosokawa, Y; Pollak, M R; Brown, E M et al. (1995) Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab 80:3107-10
Chou, Y H; Pollak, M R; Brandi, M L et al. (1995) Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am J Hum Genet 56:1075-9
Ho, C; Conner, D A; Pollak, M R et al. (1995) A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 11:389-94
Pollak, M R; Chou, Y H; Marx, S J et al. (1994) Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 93:1108-12
Pollak, M R; Brown, E M; Estep, H L et al. (1994) Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 8:303-7
Pollak, M R; Brown, E M; Chou, Y H et al. (1993) Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297-303
Pollak, M R; Chou, Y H; Cerda, J J et al. (1993) Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat Genet 5:201-4